NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care:

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.

    See more

    Recent Press Releases

    Nanobiotix announces positive first results for novel NBTXR3 in rectal cancer study at ASCO-GI 2021
    Nanobiotix announces key development milestones for 2021 after successful Nasdaq initial public offering
    Nanobiotix announces pricing of global offering and approval to list on nasdaq global select market



    November 28-December 1, 2020

    ESTRO 2020

    More info
    January 15-17

    ASCO GI 2021

    More info


    “Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life.”

    Anne-Juliette Hermant
    Chief People Officer

    Download our latest
    Corporate Presentation